Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors

The aims of this study were (i) to evaluate the effect of talazoparib (1 mg once daily) on cardiac repolarization in patients with advanced solid tumors by assessing corrected QT interval (QTc) and (ii) to examine the relationship between plasma talazoparib concentration and QTc. In this open-label...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffman, Justin, Chakrabarti, Jayeta, Plotka, Anna, Milillo Naraine, Adriana, Kanamori, David, Moroose, Rebecca, Nguyen, Linh, Wang, Diane, Wainberg, Zev A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Clinical Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485310/
https://www.ncbi.nlm.nih.gov/pubmed/30875341
http://dx.doi.org/10.1097/CAD.0000000000000772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485310/
https://www.ncbi.nlm.nih.gov/pubmed/30875341
http://dx.doi.org/10.1097/CAD.0000000000000772

Ejemplares similares